Immix Biopharma (IMMX) FDA Approvals $8.57 -0.37 (-4.09%) As of 03:23 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Upcoming FDA Events for Immix Biopharma Immix Biopharma (IMMX) has upcoming FDA regulatory milestones for NXC-201. The table below outlines estimated target dates and event types for these pending regulatory actions. DrugTarget DateAnnouncement NXC-201Q3 2026Top-line resultsImmix Biopharma, Inc. announced that NEXICART-2 enrollment is complete, meeting Company guidance, with topline results expected in Q3 2026, followed by BLA submission and planned commercial launch. (March 30, 2026) Immix Biopharma's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Immix Biopharma (IMMX). Over the past two years, Immix Biopharma has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as NXC-201. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. NXC-201 FDA Regulatory Timeline and Events NXC-201 is a drug developed by Immix Biopharma for the following indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Top-line results - March 30,2026Top-Line Results Drug: NXC-201Announced Date: March 30, 2026Target Action Date: Q3 2026Estimated Target Date Range: July 1, 2026 - September 30, 2026Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that NEXICART-2 enrollment is complete, meeting Company guidance, with topline results expected in Q3 2026, followed by BLA submission and planned commercial launch.AI SummaryImmix Biopharma announced that enrollment in its NEXICART-2 trial is complete, meeting company guidance. NEXICART-2 is a U.S. Phase 2, registrational study of the CAR-T therapy NXC-201 for relapsed/refractory AL amyloidosis and enrolled 40 patients across multiple sites. The company says topline results are expected in Q3 2026. Topline results are planned to be followed by a Biologics License Application (BLA) submission and a planned commercial launch, pending the outcomes and regulatory review. Immix describes NEXICART-2 as a BLA-enabling study that could advance NXC-201 toward marketing approval. Immix also announced a new Chief Medical Officer, recruited from Merck and Johnson & Johnson, who will lead clinical and regulatory strategy for the BLA submission and help prepare the company for potential commercialization.Read AnnouncementDesignation Grant - January 28,2026Designation Grant Breakthrough TherapyDrug: NXC-201Announced Date: January 28, 2026Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.AI SummaryImmix Biopharma announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL amyloidosis. The designation was awarded based on positive interim Phase 2 results from the NEXICART-2 trial that were presented at the American Society of Hematology 2025 meeting. Breakthrough Therapy status is intended to speed development and review for drugs that show substantial improvement over existing therapies on important clinical measures. NEXICART-2 is a U.S. multi-site Phase 2 study of a sterically optimized CAR-T therapy, NXC-201, with a registrational design and an expected enrollment of about 40 patients. Immix said it expects final trial data this year and plans to submit a Biologics License Application (BLA) afterward. AL amyloidosis is a serious disease in which toxic light chains damage the heart, kidneys and liver. The Breakthrough designation could help bring an effective new treatment to patients faster.Read AnnouncementPositive Results - December 7,2025Positive Results Phase 2Drug: NXC-201Announced Date: December 7, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced positive phase 2 NXC-201 results in an oral presentation at ASH 2025 presented by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center.AI SummaryImmix Biopharma announced positive Phase 2 results for NXC-201 in an oral presentation at ASH 2025 by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center. NXC-201 is a BCMA‑targeted CAR‑T cell therapy being tested for relapsed/refractory AL amyloidosis. An independent review committee reported a complete response (CR) rate of 75% (15 of 20 patients) at the s/u IFE(-) level. Four of five pending patients were bone marrow MRD‑negative, which predicts future CR and could raise the CR rate to about 95%. Organ responses were seen in 70% of evaluable patients (7 of 10). No neurotoxicity was observed, and cytokine release syndrome was low‑grade with a median duration of one day. NEXICART‑2 is an ongoing U.S. multi‑site Phase 2 trial expected to enroll about 40 patients. Immix plans a final readout and a BLA submission in 2026. Investigators described the data as encouraging given limited options for this disease.Read AnnouncementPresentation - October 7,2025Presentation Drug: NXC-201Announced Date: October 7, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9, 2025, in Orlando, Florida.AI SummaryImmix Biopharma, Inc. announced it will present an abstract on NXC-201 at the American Society of Hematology (ASH) 67th Annual Meeting and Exposition December 6–9, 2025, in Orlando, Florida. AL amyloidosis is a rare disease caused by misfolded proteins from abnormal plasma cells. These proteins can build up in organs like the heart and kidneys, leading to serious complications. The U.S. prevalence of relapsed/refractory AL amyloidosis is growing, with an estimated 37,270 patients by 2025 and a global market expected to reach $6 billion. NXC-201 is a BCMA-targeted CAR-T cell therapy with a “digital filter” designed to reduce non-specific activation. It is being tested in the multi-center NEXICART-2 study in the U.S., which achieved its primary endpoint in interim results presented at ASCO 2025. The upcoming ASH presentation will share new data and insights into its safety and effectiveness.Read AnnouncementProvided Update - August 6,2025Provided Update Drug: NXC-201Announced Date: August 6, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced important updates about its plan to address other serious diseases with its sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that filters out non-specific activation.AI SummaryImmix Biopharma, Inc. today announced progress in expanding its sterically-optimized BCMA-targeted CAR-T cell therapy, NXC-201, into a range of other serious diseases (OSD). NXC-201 features a “digital filter” designed to block non-specific immune activation, potentially improving safety and efficacy across multiple conditions. The company is currently dosing patients in several OSD studies and plans additional trials. Immix intends to share detailed clinical data at upcoming scientific meetings, highlighting early signs of strong, one-and-done responses. To accelerate development, Immix will seek external partnerships to license out its OSD programs. “While we stay focused on our lead relapsed/refractory AL Amyloidosis trial for BLA submission, promising NXC-201 data could transform treatment in other diseases,” said Ilya Rachman, M.D., Ph.D., CEO. Gabriel Morris, CFO, added that these collaborations could also support the path to regulatory approval and future growth.Read AnnouncementProvided Update - July 7,2025Provided Update Drug: NXC-201Announced Date: July 7, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/refractory AL Amyloidosis.AI SummaryImmix Biopharma, Inc. has announced accelerated progress in its U.S. NEXICART-2 clinical trial focused on treating relapsed/refractory AL Amyloidosis. The company expanded the trial’s national footprint to include 18 clinical sites. This rapid advancement is a promising step toward offering a cell therapy treatment for an underserved patient population, where no FDA-approved drugs currently exist. According to CEO Ilya Rachman, M.D., Ph.D., the progress is moving faster than expected, addressing a significant unmet need across the country. CFO Gabriel Morris added that the new sites help speed up the timeline toward submitting a Biologics License Application (BLA) for FDA approval. Interim trial results have been shared at recent medical meetings, underlining the potential of this advanced cell therapy in providing new hope for patients battling AL Amyloidosis.Read AnnouncementPrimary endpoint Met - June 3,2025Primary Endpoint Met Drug: NXC-201Announced Date: June 3, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced meeting its primary endpoint of complete response (CR) rate for cell therapy NXC-201 at an oral presentation of interim results at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois.AI SummaryImmix Biopharma recently presented promising interim results at ASCO 2025 in Chicago based on its U.S. multi-center NEXICART-2 Phase 1/2 trial of NXC-201. The cell therapy achieved a 70% complete response (CR) rate, meaning 7 out of 10 patients reached a complete remission, marking the trial’s primary endpoint. The encouraging findings include no recorded relapses and no significant safety concerns, including an absence of neurotoxicity. These outcomes highlight the potential of NXC-201 as a breakthrough treatment, especially since current options for relapsed/refractory AL Amyloidosis offer less than a 10% CR rate. Following these results, Immix Biopharma is moving ahead with plans to file a Biologics License Application for FDA approval. A Key Opinion Leader event is scheduled to further discuss the significance of these findings, reinforcing the company’s progress toward addressing a critical unmet medical need in this challenging condition.Read AnnouncementEnrollment Update - May 23,2025Enrollment Update Drug: NXC-201Announced Date: May 23, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2.AI SummaryImmix Biopharma, Inc announced a significant milestone in its U.S. multi-site clinical trial NEXICART-2. The company reported that 14 U.S. sites are now actively enrolling patients for the study on its CAR-T cell therapy, NXC-201, targeting relapsed/refractory AL Amyloidosis. Notably, this update marks the addition of 10 new sites since the last report, reflecting growing national interest in advancing new treatment options for this serious condition. With patient enrollment exceeding expectations, Immix Biopharma anticipates completing the NEXICART-2 trial ahead of schedule. This rapid enrollment and expansion across leading AL Amyloidosis centers underscore the commitment to fast-track innovative therapies that may offer improved outcomes for patients. The progress of the trial is seen as a promising step forward in addressing the urgent medical needs in the AL Amyloidosis community.Read AnnouncementData Presentation - May 21,2025Data Presentation Phase 1/2Drug: NXC-201Announced Date: May 21, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that it will host a virtual Key Opinion Leader (KOL) event to discuss interim clinical data from the NEXICART-2 Phase 1/2 clinical trial of cell therapy NXC-201 in patients with relapsed/refractory AL Amyloidosis following its 2025 American Society of Clinical Oncology (ASCO) Oral Presentation in Chicago, IL.AI SummaryImmix Biopharma, Inc. announced it will hold a virtual Key Opinion Leader (KOL) event to discuss interim clinical data from its NEXICART-2 Phase 1/2 trial. The trial involves NXC-201, a cell therapy being tested in patients with relapsed or refractory AL Amyloidosis. This session comes after the company’s 2025 American Society of Clinical Oncology (ASCO) Oral Presentation in Chicago, IL. The event is scheduled for Tuesday, June 3, 2025, at 3:00 pm ET, featuring a live question-and-answer session. Key speakers include Heather Landau, MD of Memorial Sloan-Kettering Cancer Center, Shahzad Raza, MD of the Cleveland Clinic, and Jeffrey Zonder, MD of Karmanos Cancer Institute. They will share their clinical insights on the new therapy and discuss how it may change treatment options for AL Amyloidosis, offering valuable information for investors and stakeholders. Read AnnouncementDesignation Grant - February 10,2025Designation Grant RMAT DesignationDrug: NXC-201Announced Date: February 10, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed/refractory AL amyloidosis.AI SummaryImmix Biopharma recently announced that the FDA has granted RMAT designation to its sterically-optimized CAR-T cell therapy, NXC-201, for treating relapsed/refractory AL amyloidosis. This designation is based on promising proof-of-concept U.S. clinical data from the NEXICART-2 trial, emphasizing NXC-201’s potential as a new treatment option in a field with no current FDA-approved drugs. The RMAT status allows for more frequent interactions with the FDA and can help speed up the path to market through mechanisms like Accelerated Approval and Priority Review. Additionally, the enrollment pace in the NEXICART-2 trial has increased, and Immix Biopharma plans to share further updates on its progress in the first half of 2025.Read AnnouncementProvided Update - January 7,2025Provided Update Phase 1bDrug: NXC-201Announced Date: January 7, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced successful completion of the six-patient Phase 1b safety run-in segment in the U.S.AI SummaryImmix Biopharma, Inc. announced that it has successfully completed dosing all six patients in the Phase 1b safety run-in segment of its NEXICART-2 study in the U.S. The study is testing the CAR-T therapy NXC-201 for patients with relapsed/refractory AL Amyloidosis, a serious disease affecting thousands of people. Three patients received a dose of 150 million targeted cells and three received 450 million targeted cells. All participants completed their post-dosing safety evaluations, which demonstrates a good safety profile. This milestone now paves the way for accelerated enrollment at U.S. study sites starting in January 2025. The progress of this trial moves the company closer to providing a potential new treatment option for AL Amyloidosis, emphasizing the promising role of NXC-201 as the only one-time CAR-T therapy currently under development for this condition.Read AnnouncementInitial Data - December 19,2024Initial Data Drug: NXC-201Announced Date: December 19, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced initial clinical data from the first four patients in the ongoing NEXICART-2 (NCT06097832) U.S.AI SummaryImmix Biopharma, Inc. announced promising initial clinical data from the first four patients in its ongoing U.S. NEXICART-2 trial (NCT06097832) evaluating NXC-201, a CAR-T cell therapy for relapsed/refractory AL Amyloidosis. In the study, all four patients normalized their disease markers within 30 days after dosing. Two patients have already been classified as complete responders, while the other two are bone marrow MRD negative—indicating they could soon achieve complete response. The data, with a median follow-up of 85 days, show that NXC-201 led to rapid and deep responses, with some patients normalizing markers as early as seven days post-infusion. Immix Biopharma plans to continue enrolling patients and will provide further updates in the first half of 2025, as they further evaluate the therapy’s potential benefits for patients with preserved heart function.Read AnnouncementResults - December 16,2024Results Drug: NXC-201Announced Date: December 16, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that the Journal of Clinical Oncology (JCO) published NXC-201 clinical results in relapsed/refractory AL Amyloidosis.AI SummaryImmix Biopharma, Inc. announced that the Journal of Clinical Oncology published the promising clinical results of NXC-201, a new CAR-T therapy for relapsed/refractory AL Amyloidosis. In the ex-U.S. NEXICART-1 trial, 16 patients who previously underwent multiple treatment lines received NXC-201, resulting in a 75% complete response rate. The therapy produced rapid and deep responses even in frail, heavily pre-treated patients and showed a favorable safety profile with minimal adverse effects. These results mark a significant step for NXC-201 as a potential new treatment option for patients with relapsed/refractory AL Amyloidosis, a condition with limited treatment choices. With these encouraging findings published in JCO, Immix Biopharma is building on this success through further U.S. studies targeting patients with preserved heart function, aiming to confirm the long-term benefits and safety of NXC-201.Read AnnouncementProvided Update - October 2,2024Provided Update Drug: NXC-201Announced Date: October 2, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced advances in the NEXICART-2 clinical study of its CAR-T NXC-201 for relapsed/refractory AL Amyloidosis, a plasma cell disorder that leads to progressive damage to the heart, kidney and liver, which currently affects approximately 33,000 patients in the U.S. Immix Biopharma's sterically-optimized CAR-T NXC-201 is the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials.AI SummaryImmix Biopharma, Inc. announced significant progress in its NEXICART-2 clinical study evaluating CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis. This plasma cell disorder causes progressive damage to the heart, kidney, and liver and impacts approximately 33,000 patients in the U.S. The study, now advancing at a dose expansion level of 450 million CAR+T cells, follows an initial successful cohort at 150 million cells, where complete responses were observed in prior clinical studies. NXC-201 is currently the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials. Spearheaded at Memorial Sloan Kettering Cancer Center among other sites, the trial reflects strong investigator enthusiasm and a promising step forward toward a new treatment option for patients facing this significant unmet medical need.Read AnnouncementProvided Update - August 28,2024Provided Update Drug: NXC-201Announced Date: August 28, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced the addition of three additional clinical trial sites for its U.S. relapsed/refractory AL Amyloidosis clinical trial NEXICART-2.AI SummaryImmix Biopharma, Inc. has expanded its U.S. clinical trial footprint for the relapsed/refractory AL Amyloidosis study NEXICART-2 by adding three new sites. The newly added centers are Cleveland Clinic, UC Davis, and Sutter Health, which will work alongside Memorial Sloan Kettering Cancer Center (MSKCC), the lead clinical site. This Phase 1b/2 trial focuses on evaluating the safety and efficacy of the CAR-T therapy NXC-201 in patients with AL Amyloidosis who have adequate cardiac function and have not been treated with BCMA-targeted therapy. The addition of these top-tier clinical sites is expected to increase patient access and enrollment opportunities while enhancing the quality of data collected. Immix Biopharma’s expanded network underscores its commitment to advancing treatment options for patients with this challenging condition.Read AnnouncementProvided Update - July 25,2024Provided Update Drug: NXC-201Announced Date: July 25, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has awarded Immix Biopharma cell therapy division Nexcella an $8 million CLIN2 grant award to support clinical development of chimeric antigen receptor T-cell (CAR-T) therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.AI SummaryImmix Biopharma, Inc. announced that its cell therapy division, Nexcella, has been awarded an $8 million CLIN2 grant by the California Institute for Regenerative Medicine (CIRM). This funding is aimed at supporting the clinical development of their innovative chimeric antigen receptor T-cell (CAR-T) therapy, NXC-201, designed for patients with relapsed/refractory AL Amyloidosis. AL Amyloidosis is a rare disease with high unmet medical needs, as current treatment options often have severe side effects and limited long-term success. The grant from CIRM highlights the promise of NXC-201 as a one-time treatment that could potentially offer improved tolerability and sustained remissions for patients. Immix Biopharma plans to further evaluate the safety and efficacy of NXC-201 in ongoing clinical trials, building on positive preliminary data that supports its potential use in this difficult-to-treat condition.Read AnnouncementDose Update - July 8,2024Dose Update Drug: NXC-201Announced Date: July 8, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc announced that the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy..AI SummaryImmix Biopharma, Inc. announced that the first patient has been dosed at Memorial Sloan Kettering Cancer Center (MSKCC) in its U.S. NEXICART-2 trial. The trial is testing NXC-201, a sterically optimized BCMA-targeted CAR-T cell therapy, designed to treat relapsed/refractory AL Amyloidosis. Patients enrolled in this study must have adequate cardiac function and have not received prior BCMA-targeted treatments. The trial will help evaluate the safety and effectiveness of NXC-201 in a patient group with limited treatment options. Positive results from the earlier ex-U.S. NEXICART-1 study, which reported a 92% overall response rate, have built excitement for NXC-201. Healthcare professionals are hopeful that this one-time CAR-T cell therapy could provide a new treatment option for AL Amyloidosis patients who have exhausted other therapies, marking an important step in advancing care for this challenging condition.Read Announcement Immix Biopharma FDA Events - Frequently Asked Questions Has Immix Biopharma received FDA approval? As of now, Immix Biopharma (IMMX) has not received any FDA approvals for its therapy in the last two years. What drugs has Immix Biopharma submitted to the FDA? In the past two years, Immix Biopharma (IMMX) has reported FDA regulatory activity for NXC-201. What is the most recent FDA event for Immix Biopharma? The most recent FDA-related event for Immix Biopharma occurred on March 30, 2026, involving NXC-201. The update was categorized as "Top-line results," with the company reporting: "Immix Biopharma, Inc. announced that NEXICART-2 enrollment is complete, meeting Company guidance, with topline results expected in Q3 2026, followed by BLA submission and planned commercial launch." What conditions do Immix Biopharma's current drugs treat? Currently, Immix Biopharma has one therapy (NXC-201) targeting the following condition: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagio Medical FDA EventsBioCardia FDA EventsCognition Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsPrecision BioSciences FDA EventsHUTCHMED FDA EventsEli Lilly and Company FDA EventsTeleflex FDA EventsBioMarin Pharmaceutical FDA EventsDiaMedica Therapeutics FDA EventsDyne Therapeutics FDA EventsGuardant Health FDA EventsLigand Pharmaceuticals FDA EventsMadrigal Pharmaceuticals FDA EventsMetaVia FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Pharvaris FDA Events Mesoblast FDA Events Trevi Therapeutics FDA Events Stoke Therapeutics FDA Events ANI Pharmaceuticals FDA Events Zymeworks FDA Events Ascentage Pharma Group International FDA Events Harmony Biosciences FDA Events Vericel FDA Events Sarepta Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:IMMX last updated on 3/30/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Top-line results - March 30,2026Top-Line Results Drug: NXC-201Announced Date: March 30, 2026Target Action Date: Q3 2026Estimated Target Date Range: July 1, 2026 - September 30, 2026Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that NEXICART-2 enrollment is complete, meeting Company guidance, with topline results expected in Q3 2026, followed by BLA submission and planned commercial launch.AI SummaryImmix Biopharma announced that enrollment in its NEXICART-2 trial is complete, meeting company guidance. NEXICART-2 is a U.S. Phase 2, registrational study of the CAR-T therapy NXC-201 for relapsed/refractory AL amyloidosis and enrolled 40 patients across multiple sites. The company says topline results are expected in Q3 2026. Topline results are planned to be followed by a Biologics License Application (BLA) submission and a planned commercial launch, pending the outcomes and regulatory review. Immix describes NEXICART-2 as a BLA-enabling study that could advance NXC-201 toward marketing approval. Immix also announced a new Chief Medical Officer, recruited from Merck and Johnson & Johnson, who will lead clinical and regulatory strategy for the BLA submission and help prepare the company for potential commercialization.Read Announcement
Designation Grant - January 28,2026Designation Grant Breakthrough TherapyDrug: NXC-201Announced Date: January 28, 2026Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.AI SummaryImmix Biopharma announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL amyloidosis. The designation was awarded based on positive interim Phase 2 results from the NEXICART-2 trial that were presented at the American Society of Hematology 2025 meeting. Breakthrough Therapy status is intended to speed development and review for drugs that show substantial improvement over existing therapies on important clinical measures. NEXICART-2 is a U.S. multi-site Phase 2 study of a sterically optimized CAR-T therapy, NXC-201, with a registrational design and an expected enrollment of about 40 patients. Immix said it expects final trial data this year and plans to submit a Biologics License Application (BLA) afterward. AL amyloidosis is a serious disease in which toxic light chains damage the heart, kidneys and liver. The Breakthrough designation could help bring an effective new treatment to patients faster.Read Announcement
Positive Results - December 7,2025Positive Results Phase 2Drug: NXC-201Announced Date: December 7, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced positive phase 2 NXC-201 results in an oral presentation at ASH 2025 presented by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center.AI SummaryImmix Biopharma announced positive Phase 2 results for NXC-201 in an oral presentation at ASH 2025 by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center. NXC-201 is a BCMA‑targeted CAR‑T cell therapy being tested for relapsed/refractory AL amyloidosis. An independent review committee reported a complete response (CR) rate of 75% (15 of 20 patients) at the s/u IFE(-) level. Four of five pending patients were bone marrow MRD‑negative, which predicts future CR and could raise the CR rate to about 95%. Organ responses were seen in 70% of evaluable patients (7 of 10). No neurotoxicity was observed, and cytokine release syndrome was low‑grade with a median duration of one day. NEXICART‑2 is an ongoing U.S. multi‑site Phase 2 trial expected to enroll about 40 patients. Immix plans a final readout and a BLA submission in 2026. Investigators described the data as encouraging given limited options for this disease.Read Announcement
Presentation - October 7,2025Presentation Drug: NXC-201Announced Date: October 7, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67th Annual Meeting and Exposition to be held December 6-9, 2025, in Orlando, Florida.AI SummaryImmix Biopharma, Inc. announced it will present an abstract on NXC-201 at the American Society of Hematology (ASH) 67th Annual Meeting and Exposition December 6–9, 2025, in Orlando, Florida. AL amyloidosis is a rare disease caused by misfolded proteins from abnormal plasma cells. These proteins can build up in organs like the heart and kidneys, leading to serious complications. The U.S. prevalence of relapsed/refractory AL amyloidosis is growing, with an estimated 37,270 patients by 2025 and a global market expected to reach $6 billion. NXC-201 is a BCMA-targeted CAR-T cell therapy with a “digital filter” designed to reduce non-specific activation. It is being tested in the multi-center NEXICART-2 study in the U.S., which achieved its primary endpoint in interim results presented at ASCO 2025. The upcoming ASH presentation will share new data and insights into its safety and effectiveness.Read Announcement
Provided Update - August 6,2025Provided Update Drug: NXC-201Announced Date: August 6, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced important updates about its plan to address other serious diseases with its sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a "digital filter" that filters out non-specific activation.AI SummaryImmix Biopharma, Inc. today announced progress in expanding its sterically-optimized BCMA-targeted CAR-T cell therapy, NXC-201, into a range of other serious diseases (OSD). NXC-201 features a “digital filter” designed to block non-specific immune activation, potentially improving safety and efficacy across multiple conditions. The company is currently dosing patients in several OSD studies and plans additional trials. Immix intends to share detailed clinical data at upcoming scientific meetings, highlighting early signs of strong, one-and-done responses. To accelerate development, Immix will seek external partnerships to license out its OSD programs. “While we stay focused on our lead relapsed/refractory AL Amyloidosis trial for BLA submission, promising NXC-201 data could transform treatment in other diseases,” said Ilya Rachman, M.D., Ph.D., CEO. Gabriel Morris, CFO, added that these collaborations could also support the path to regulatory approval and future growth.Read Announcement
Provided Update - July 7,2025Provided Update Drug: NXC-201Announced Date: July 7, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced accelerated U.S. NEXICART-2 clinical trial progress in relapsed/refractory AL Amyloidosis.AI SummaryImmix Biopharma, Inc. has announced accelerated progress in its U.S. NEXICART-2 clinical trial focused on treating relapsed/refractory AL Amyloidosis. The company expanded the trial’s national footprint to include 18 clinical sites. This rapid advancement is a promising step toward offering a cell therapy treatment for an underserved patient population, where no FDA-approved drugs currently exist. According to CEO Ilya Rachman, M.D., Ph.D., the progress is moving faster than expected, addressing a significant unmet need across the country. CFO Gabriel Morris added that the new sites help speed up the timeline toward submitting a Biologics License Application (BLA) for FDA approval. Interim trial results have been shared at recent medical meetings, underlining the potential of this advanced cell therapy in providing new hope for patients battling AL Amyloidosis.Read Announcement
Primary endpoint Met - June 3,2025Primary Endpoint Met Drug: NXC-201Announced Date: June 3, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced meeting its primary endpoint of complete response (CR) rate for cell therapy NXC-201 at an oral presentation of interim results at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois.AI SummaryImmix Biopharma recently presented promising interim results at ASCO 2025 in Chicago based on its U.S. multi-center NEXICART-2 Phase 1/2 trial of NXC-201. The cell therapy achieved a 70% complete response (CR) rate, meaning 7 out of 10 patients reached a complete remission, marking the trial’s primary endpoint. The encouraging findings include no recorded relapses and no significant safety concerns, including an absence of neurotoxicity. These outcomes highlight the potential of NXC-201 as a breakthrough treatment, especially since current options for relapsed/refractory AL Amyloidosis offer less than a 10% CR rate. Following these results, Immix Biopharma is moving ahead with plans to file a Biologics License Application for FDA approval. A Key Opinion Leader event is scheduled to further discuss the significance of these findings, reinforcing the company’s progress toward addressing a critical unmet medical need in this challenging condition.Read Announcement
Enrollment Update - May 23,2025Enrollment Update Drug: NXC-201Announced Date: May 23, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2.AI SummaryImmix Biopharma, Inc announced a significant milestone in its U.S. multi-site clinical trial NEXICART-2. The company reported that 14 U.S. sites are now actively enrolling patients for the study on its CAR-T cell therapy, NXC-201, targeting relapsed/refractory AL Amyloidosis. Notably, this update marks the addition of 10 new sites since the last report, reflecting growing national interest in advancing new treatment options for this serious condition. With patient enrollment exceeding expectations, Immix Biopharma anticipates completing the NEXICART-2 trial ahead of schedule. This rapid enrollment and expansion across leading AL Amyloidosis centers underscore the commitment to fast-track innovative therapies that may offer improved outcomes for patients. The progress of the trial is seen as a promising step forward in addressing the urgent medical needs in the AL Amyloidosis community.Read Announcement
Data Presentation - May 21,2025Data Presentation Phase 1/2Drug: NXC-201Announced Date: May 21, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that it will host a virtual Key Opinion Leader (KOL) event to discuss interim clinical data from the NEXICART-2 Phase 1/2 clinical trial of cell therapy NXC-201 in patients with relapsed/refractory AL Amyloidosis following its 2025 American Society of Clinical Oncology (ASCO) Oral Presentation in Chicago, IL.AI SummaryImmix Biopharma, Inc. announced it will hold a virtual Key Opinion Leader (KOL) event to discuss interim clinical data from its NEXICART-2 Phase 1/2 trial. The trial involves NXC-201, a cell therapy being tested in patients with relapsed or refractory AL Amyloidosis. This session comes after the company’s 2025 American Society of Clinical Oncology (ASCO) Oral Presentation in Chicago, IL. The event is scheduled for Tuesday, June 3, 2025, at 3:00 pm ET, featuring a live question-and-answer session. Key speakers include Heather Landau, MD of Memorial Sloan-Kettering Cancer Center, Shahzad Raza, MD of the Cleveland Clinic, and Jeffrey Zonder, MD of Karmanos Cancer Institute. They will share their clinical insights on the new therapy and discuss how it may change treatment options for AL Amyloidosis, offering valuable information for investors and stakeholders. Read Announcement
Designation Grant - February 10,2025Designation Grant RMAT DesignationDrug: NXC-201Announced Date: February 10, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed/refractory AL amyloidosis.AI SummaryImmix Biopharma recently announced that the FDA has granted RMAT designation to its sterically-optimized CAR-T cell therapy, NXC-201, for treating relapsed/refractory AL amyloidosis. This designation is based on promising proof-of-concept U.S. clinical data from the NEXICART-2 trial, emphasizing NXC-201’s potential as a new treatment option in a field with no current FDA-approved drugs. The RMAT status allows for more frequent interactions with the FDA and can help speed up the path to market through mechanisms like Accelerated Approval and Priority Review. Additionally, the enrollment pace in the NEXICART-2 trial has increased, and Immix Biopharma plans to share further updates on its progress in the first half of 2025.Read Announcement
Provided Update - January 7,2025Provided Update Phase 1bDrug: NXC-201Announced Date: January 7, 2025Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced successful completion of the six-patient Phase 1b safety run-in segment in the U.S.AI SummaryImmix Biopharma, Inc. announced that it has successfully completed dosing all six patients in the Phase 1b safety run-in segment of its NEXICART-2 study in the U.S. The study is testing the CAR-T therapy NXC-201 for patients with relapsed/refractory AL Amyloidosis, a serious disease affecting thousands of people. Three patients received a dose of 150 million targeted cells and three received 450 million targeted cells. All participants completed their post-dosing safety evaluations, which demonstrates a good safety profile. This milestone now paves the way for accelerated enrollment at U.S. study sites starting in January 2025. The progress of this trial moves the company closer to providing a potential new treatment option for AL Amyloidosis, emphasizing the promising role of NXC-201 as the only one-time CAR-T therapy currently under development for this condition.Read Announcement
Initial Data - December 19,2024Initial Data Drug: NXC-201Announced Date: December 19, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced initial clinical data from the first four patients in the ongoing NEXICART-2 (NCT06097832) U.S.AI SummaryImmix Biopharma, Inc. announced promising initial clinical data from the first four patients in its ongoing U.S. NEXICART-2 trial (NCT06097832) evaluating NXC-201, a CAR-T cell therapy for relapsed/refractory AL Amyloidosis. In the study, all four patients normalized their disease markers within 30 days after dosing. Two patients have already been classified as complete responders, while the other two are bone marrow MRD negative—indicating they could soon achieve complete response. The data, with a median follow-up of 85 days, show that NXC-201 led to rapid and deep responses, with some patients normalizing markers as early as seven days post-infusion. Immix Biopharma plans to continue enrolling patients and will provide further updates in the first half of 2025, as they further evaluate the therapy’s potential benefits for patients with preserved heart function.Read Announcement
Results - December 16,2024Results Drug: NXC-201Announced Date: December 16, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that the Journal of Clinical Oncology (JCO) published NXC-201 clinical results in relapsed/refractory AL Amyloidosis.AI SummaryImmix Biopharma, Inc. announced that the Journal of Clinical Oncology published the promising clinical results of NXC-201, a new CAR-T therapy for relapsed/refractory AL Amyloidosis. In the ex-U.S. NEXICART-1 trial, 16 patients who previously underwent multiple treatment lines received NXC-201, resulting in a 75% complete response rate. The therapy produced rapid and deep responses even in frail, heavily pre-treated patients and showed a favorable safety profile with minimal adverse effects. These results mark a significant step for NXC-201 as a potential new treatment option for patients with relapsed/refractory AL Amyloidosis, a condition with limited treatment choices. With these encouraging findings published in JCO, Immix Biopharma is building on this success through further U.S. studies targeting patients with preserved heart function, aiming to confirm the long-term benefits and safety of NXC-201.Read Announcement
Provided Update - October 2,2024Provided Update Drug: NXC-201Announced Date: October 2, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced advances in the NEXICART-2 clinical study of its CAR-T NXC-201 for relapsed/refractory AL Amyloidosis, a plasma cell disorder that leads to progressive damage to the heart, kidney and liver, which currently affects approximately 33,000 patients in the U.S. Immix Biopharma's sterically-optimized CAR-T NXC-201 is the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials.AI SummaryImmix Biopharma, Inc. announced significant progress in its NEXICART-2 clinical study evaluating CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis. This plasma cell disorder causes progressive damage to the heart, kidney, and liver and impacts approximately 33,000 patients in the U.S. The study, now advancing at a dose expansion level of 450 million CAR+T cells, follows an initial successful cohort at 150 million cells, where complete responses were observed in prior clinical studies. NXC-201 is currently the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials. Spearheaded at Memorial Sloan Kettering Cancer Center among other sites, the trial reflects strong investigator enthusiasm and a promising step forward toward a new treatment option for patients facing this significant unmet medical need.Read Announcement
Provided Update - August 28,2024Provided Update Drug: NXC-201Announced Date: August 28, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced the addition of three additional clinical trial sites for its U.S. relapsed/refractory AL Amyloidosis clinical trial NEXICART-2.AI SummaryImmix Biopharma, Inc. has expanded its U.S. clinical trial footprint for the relapsed/refractory AL Amyloidosis study NEXICART-2 by adding three new sites. The newly added centers are Cleveland Clinic, UC Davis, and Sutter Health, which will work alongside Memorial Sloan Kettering Cancer Center (MSKCC), the lead clinical site. This Phase 1b/2 trial focuses on evaluating the safety and efficacy of the CAR-T therapy NXC-201 in patients with AL Amyloidosis who have adequate cardiac function and have not been treated with BCMA-targeted therapy. The addition of these top-tier clinical sites is expected to increase patient access and enrollment opportunities while enhancing the quality of data collected. Immix Biopharma’s expanded network underscores its commitment to advancing treatment options for patients with this challenging condition.Read Announcement
Provided Update - July 25,2024Provided Update Drug: NXC-201Announced Date: July 25, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has awarded Immix Biopharma cell therapy division Nexcella an $8 million CLIN2 grant award to support clinical development of chimeric antigen receptor T-cell (CAR-T) therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.AI SummaryImmix Biopharma, Inc. announced that its cell therapy division, Nexcella, has been awarded an $8 million CLIN2 grant by the California Institute for Regenerative Medicine (CIRM). This funding is aimed at supporting the clinical development of their innovative chimeric antigen receptor T-cell (CAR-T) therapy, NXC-201, designed for patients with relapsed/refractory AL Amyloidosis. AL Amyloidosis is a rare disease with high unmet medical needs, as current treatment options often have severe side effects and limited long-term success. The grant from CIRM highlights the promise of NXC-201 as a one-time treatment that could potentially offer improved tolerability and sustained remissions for patients. Immix Biopharma plans to further evaluate the safety and efficacy of NXC-201 in ongoing clinical trials, building on positive preliminary data that supports its potential use in this difficult-to-treat condition.Read Announcement
Dose Update - July 8,2024Dose Update Drug: NXC-201Announced Date: July 8, 2024Indication: NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis.AnnouncementImmix Biopharma, Inc announced that the 1st patient has been dosed at MSKCC in its U.S. NEXICART-2 trial with NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy..AI SummaryImmix Biopharma, Inc. announced that the first patient has been dosed at Memorial Sloan Kettering Cancer Center (MSKCC) in its U.S. NEXICART-2 trial. The trial is testing NXC-201, a sterically optimized BCMA-targeted CAR-T cell therapy, designed to treat relapsed/refractory AL Amyloidosis. Patients enrolled in this study must have adequate cardiac function and have not received prior BCMA-targeted treatments. The trial will help evaluate the safety and effectiveness of NXC-201 in a patient group with limited treatment options. Positive results from the earlier ex-U.S. NEXICART-1 study, which reported a 92% overall response rate, have built excitement for NXC-201. Healthcare professionals are hopeful that this one-time CAR-T cell therapy could provide a new treatment option for AL Amyloidosis patients who have exhausted other therapies, marking an important step in advancing care for this challenging condition.Read Announcement
